Equities research analysts expect Minerva Surgical Inc (NASDAQ:UTRS – Get Rating) to post $10.91 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Minerva Surgical’s earnings, with the highest sales estimate coming in at $12.25 million and the lowest estimate coming in at $10.22 million. The company is scheduled to report its next earnings results on Monday, January 1st.
On average, analysts expect that Minerva Surgical will report full-year sales of $61.21 million for the current year, with estimates ranging from $60.18 million to $61.86 million. For the next financial year, analysts forecast that the business will report sales of $81.21 million, with estimates ranging from $80.52 million to $81.62 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Minerva Surgical.
Several equities analysts have issued reports on UTRS shares. Piper Sandler dropped their price objective on Minerva Surgical from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Wednesday, March 9th. Zacks Investment Research downgraded shares of Minerva Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, March 12th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Minerva Surgical presently has an average rating of “Buy” and an average target price of $11.70.
NASDAQ:UTRS traded down $0.04 during trading hours on Friday, hitting $4.34. The company’s stock had a trading volume of 25,030 shares, compared to its average volume of 14,204. The company has a fifty day simple moving average of $4.97. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.29 and a quick ratio of 2.60. Minerva Surgical has a 52-week low of $4.16 and a 52-week high of $10.37.
About Minerva Surgical (Get Rating)
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Minerva Surgical is based in SANTA CLARA, Calif.
- Get a free copy of the StockNews.com research report on Minerva Surgical (UTRS)
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- Tilray Stock Has Better Days Ahead
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.